AbbVie Stock Hits Day Low of $207.71 Amid Price Pressure

AbbVie, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 5.2%. The stock reached an intraday low of USD 207.71, reflecting a challenging trading session. Over the past week, AbbVie has seen a decrease of 8.49%, while its performance over the past month shows a decline of 8.91%. In comparison to the broader market, AbbVie’s performance has lagged behind the S&P 500, which fell by 1.36% today and 2.23% over the past week. Year-to-date, AbbVie’s stock has decreased by 8.82%, contrasting sharply with the S&P 500's decline of 3.23%. Financial metrics indicate that AbbVie is facing pressures, with a high debt-to-equity ratio and a low inventory turnover ratio of 3.69 times. The company’s cash and equivalents stand at USD 11,643 million, while its quarterly interest expenses have reached USD 782 million. Despite a notable 35.09% increase over the past three years, the stock's recent performance raises questions about its long-term stability in a competitive market.